Market capitalization | $15.24b |
Enterprise Value | $12.77b |
P/E (TTM) P/E ratio | 15.74 |
EV/FCF (TTM) EV/FCF | 14.50 |
EV/Sales (TTM) EV/Sales | 4.88 |
P/S ratio (TTM) P/S ratio | 5.83 |
P/B ratio (TTM) P/B ratio | 2.67 |
Revenue growth (TTM) Revenue growth | 23.96% |
Revenue (TTM) Revenue | $2.62b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
16 Analysts have issued a United Therapeutics Corporation forecast:
16 Analysts have issued a United Therapeutics Corporation forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 985 985 |
35%
35%
|
|
Depreciation and Amortization | 53 53 |
4%
4%
|
|
Stock Compensation | 39 39 |
63%
63%
|
|
Operating Cash Flow | 978 978 |
23%
23%
|
|
Investments | 230 230 |
66%
66%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 748 748 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Head office | United States |
CEO | Martine Rothblatt |
Employees | 1,168 |
Founded | 1996 |
Website | www.unither.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.